GENE ONLINE|News &
Opinion
Blog

2021-09-30| M&A

Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset

by Rajaneesh K. Gopinath
Share To
New Jersey-based Merck announced its plan to acquire Acceleron for $11.5 billion ($180 per share) in an all-cash deal that amounts to a whopping 38.5% premium of Acceleron's stock value in September.

The announcement was not unexpected as news trickled through the grapevine last week that a major pharma company is in talks with Acceleron for a potential buyout. On Monday, the Wall Street Journal reported that Merck was the highest bidder, edging out fellow competitors like Bristol Myers Squibb.

The acquisition will let Merck lay its hands on Acceleron's lead cardiovascular candidate, sotatercept, an investigational reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling in patients with pulmonary arterial hypertension (PAH), a rare, progressive, and life-threatening blood vessel disorder. However, Merck might have to divest its own PAH asset, Adempas, an oral sGC stimulator it gained through a 2014 deal with Bayer, over concerns of market monopoly.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top